The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma.
Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.
Biosimilars have shown to be cost-effective treatments in oncology and hematology, according to Jacopo Giuliani, MD.
Treatment with umbralisib monotherapy demonstrated improved overall response rates among patients with follicular lymphoma.
The international retrospective study included 365 patients with newly diagnosed early-stage follicular lymphoma rigorously staged with PET-CT and bone marrow biopsy.
Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues.
A new study evaluated whether the m7-FLIPI score in patients with follicular lymphoma treated with rituximab without chemotherapy can indicate prognosis.
Researchers conducted a study to determine if low levels of immune infiltration were associated with inferior outcomes among patients with follicular lymphoma.
While many patients with follicular lymphoma did well with this new regimen, the majority of those who did have disease progression had transformed disease.
Patients with follicular lymphoma who were minimal residual disease-positive after undergoing involved field radiation therapy were given rituximab to see how it affected progression-free survival.